Clinical trial
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
NCT02698176
Study timeline
Study start (actual)2016-05-04Date precision: day
Registry last updated2021-01-27
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
NUT Midline Carcinoma (NMC)unresolved
Triple Negative Breast Cancer (TNBC)unresolved
Non-small Cell Lung Cancer (NSCLC)unresolved
Interventions
BirabresibDRUG
Sponsors & collaborators
Merck Sharp & Dohme LLClead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02698176 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.